A 58-year-old man with a history of nonischemic cardiomyopathy is evaluated during a routi… — USMLE Step 3

A 58-year-old man with a history of nonischemic cardiomyopathy is evaluated during a routine follow-up appointment. His left ventricular ejection fraction was $28\%$ on an echocardiogram performed 1 week ago. The patient reports stable but persistent exertional dyspnea (New York Heart Association class II). His current daily medications include maximally tolerated lisinopril, carvedilol, dapagliflozin, and spironolactone. His vital signs are temperature $37.0^\circ\text{C}$ ( $98.6^\circ\text{F}$ ), blood pressure $118/76\text{ mmHg}$ , and heart rate $68\text{/min}$ . Physical examination reveals clear lungs and trace bilateral pedal edema. Laboratory studies show a serum potassium of $4.2\text{ mEq/L}$ and creatinine of $1.1\text{ mg/dL}$ . The physician plans to discontinue lisinopril and initiate sacubitril-valsartan to optimize guideline-directed medical therapy.

Which of the following are required components of the transition protocol and short-term monitoring plan for this patient? (Select 2)

Enforce a minimum 36-hour washout period after the final dose of lisinopril before starting sacubitril-valsartanAnswer
B
Utilize serial brain natriuretic peptide (BNP) measurements to assess therapeutic response over the next month
Evaluate serum potassium and creatinine levels 1 to 2 weeks after initiating the new therapyAnswer
D
Schedule a repeat transthoracic echocardiogram in 4 weeks to determine eligibility for an implantable cardioverter-defibrillator
E
Discontinue spironolactone prior to the transition to prevent life-threatening hyperkalemia

Answer

The necessary steps are to enforce a 36-hour washout period after stopping the ACE inhibitor and to check serum potassium and creatinine levels 1 to 2 weeks after initiating the ARNI.

Transitioning a patient from an ACE inhibitor to an angiotensin receptor-neprilysin inhibitor (ARNI) requires specific safety protocols and monitoring. First, a strict 36-hour washout period is mandatory between the last dose of the ACE inhibitor and the first dose of the ARNI. Because both medications increase bradykinin levels, overlapping their administration significantly increases the risk of life-threatening angioedema. Second, like other renin-angiotensin-aldosterone system (RAAS) inhibitors, ARNIs can cause hyperkalemia and acute kidney injury due to changes in renal hemodynamics. Current guidelines mandate checking a basic metabolic panel to assess serum potassium and creatinine within 1 to 2 weeks after initiation or dose escalation.

Step-by-Step Solution

Identify the specific pharmacological transition occurring in the clinical vignette.

The patient is being switched from an ACE inhibitor (lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI; sacubitril-valsartan).

Different medication transitions carry unique interaction risks and protocol requirements.

Determine the safety protocols required for initiating an ARNI after an ACE inhibitor.

A strict 36-hour washout period is required between the last dose of lisinopril and the first dose of sacubitril-valsartan.

Both ACE inhibitors and neprilysin inhibitors increase bradykinin levels. Overlapping therapy poses a severe risk of life-threatening angioedema.

Identify the appropriate laboratory monitoring required after initiating an ARNI.

A basic metabolic panel must be drawn in 1 to 2 weeks to evaluate serum potassium and creatinine.

Like other RAAS inhibitors, ARNIs can cause hyperkalemia and acute kidney injury, particularly in patients taking concomitant mineralocorticoid receptor antagonists (spironolactone).

Evaluate the remaining options for clinical appropriateness.

Routine BNP monitoring is invalid, ICD reassessment at 4 weeks is premature, and stopping spironolactone inappropriately removes a mortality-benefit therapy.

To systematically eliminate common distractors related to heart failure management and biomarker interpretation.

Key Concept

Transitioning a patient from an ACE inhibitor to an ARNI requires a mandatory 36-hour washout period to prevent angioedema, followed by renal function and potassium monitoring in 1 to 2 weeks.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic